• Username (E-mail)
  • Password
Dow 20,761 -0.2%  EStoxx50 3,304 -0.9%  Nikkei 19,284 -0.5%  EUR 1.0568 -0.1% 
Nasdaq 5,826 -0.2%  FTSE100 7,244 -0.4%  Yen 112.1080 -0.5%  Oil 56.0 -0.8% 
S&P500 2,359 -0.2%  DAX 11,804 -1.2%  GBP 1.2462 -0.7%  Gold 1,257 0.6% 

Amgen share [Symbol: AMGN / ISIN: US0311621009]

Realtimequote Amgen Inc. in USD

Exchange Market
173.64
Last
95,298
Volume
Time 02:25 PM
02/24/2017 02:25:40 PM UTC-0500
activate push

Stock Price Amgen Inc. in USD

Activate push
173.61 USD -0.40 USD -0.23 %
Trade Time 2:10 PM Trade Date 2/24/2017
Daily High 174.60 Open 173.29
Daily Low 172.48 Prev. Close 174.01
52-week High 176.85 Volume (Qty.) 554,292
52-week Low 133.64 Market Cap (USD) 128.50 B
52-week Perf.
Exchange

Analyst Opinions for Amgen Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
08/26/13
Amgen Independent Research GmbH
04/03/13
Amgen Independent Research GmbH
02/15/13
Amgen Independent Research GmbH
12/17/12
Amgen RBC Capital Markets
12/17/12
Amgen Independent Research GmbH

Moody's Rating for Amgen Inc.

Investment Grade (High Grade)
Investment Grade (Medium Grade)
Speculative Grade
Rating Baa1
Rating Update NEW
Date of Rating 2/23/2016
Rating Office USA

Profile Amgen Inc.

Company Profile
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. Its products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
pagehit

Add or Edit Instrument

Amgen Chart - 1 Year - NAS
  • Intraday
  • 1w
  • 3 Mo.
  • 1y
  • 3y
  • 5y
  • Max
  • Exchange: NAS
  • Chart Options

Estimates for Amgen

2016 2017e 2018e
Dividend 4.00 4.52 4.86
Dividend Yield in % 2.71 2.59 2.79
P/E Ratio 12.69 14.06 13.60
EPS 11.65 12.41 12.83

Amgen Key Figures

Market Cap (USD) 128.50 B
Free Float in % 99.83
Number of Shares (Mio.) 736.45
Cash Flow per Share 12.10
Book Value per Share 40.53
60-Days Volatility 23.44
P/B Ratio 3.65

Base Data Amgen

Symbol AMGN
ISIN US0311621009
Indices NASDAQ Comp., S&P 500, NASDAQ 100, S&P 100, BX Swiss - USA

About the Company Amgen

Country USA

Amgen Historical Prices

02/22/2017
02/22/2017 06:00:00 PM UTC-0500
174.01 932,689
02/21/2017
02/21/2017 06:00:00 PM UTC-0500
172.61 924,708
02/20/2017
02/20/2017 06:00:00 PM UTC-0500
173.14 1,075,612
02/16/2017
02/16/2017 06:00:00 PM UTC-0500
173.29 1,561,056
02/15/2017
02/15/2017 06:00:00 PM UTC-0500
172.11 931,753

Amgen Peer Group

Agennix 0.05
-40.6%
Amgen 173.61
-0.2%
BB BIOTECH 56.70
-1.7%
Bayer 104.55
-0.4%
Biogen 283.43
-0.5%
Biotest 18.53
-5.2%
EVOTEC 7.22
-1.8%
Gilead Sciences 69.93
0.8%
MorphoSys 51.89
-2.1%
QIAGEN 26.51
-0.7%
Sanofi 80.76
0.8%

Similar shares with higher 1-year perf.